{
    "nct_id": "NCT03466411",
    "official_title": "A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease",
    "inclusion_criteria": "* Have Crohn's disease (CD) or fistulizing Crohn's disease of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy\n* Have moderate to severe CD as assessed by CDAI, stool frequency (SF), and abdominal pain (AP) scores, and Simple Endoscopic Score for Crohn's Disease (SES-CD)\n* Have screening laboratory test results within the protocol specified parameters\n* A female participant of childbearing potential must have a negative urine pregnancy test result at screening and baseline\n* Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current diagnosis of ulcerative colitis or indeterminate colitis\n* Has complications of Crohn's disease, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation\n* Unstable doses of concomitant Crohn's disease therapy\n* Receipt of Crohn's disease approved biologic agents, investigational agents, or procedures outside of permitted timeframe as specified in the protocol\n* Any medical contraindications preventing study participation",
    "miscellaneous_criteria": ""
}